Cell Therapy Manufacturing Market Landscape & Opportunity Assessment, 2019-2030

News provided by

Feb 18, 2020, 10:30 ET

DUBLIN, Feb. 18, 2020 /PRNewswire/ -- The "Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030" report has been added to ResearchAndMarkets.com's offering.

Cell Therapy Manufacturing Market (3rd Edition), 2019-2030 features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing. It focuses on both contract manufacturers, as well as developers with in-house manufacturing facilities, offering in-depth analyses of the various business entities that are engaged in this domain, across different global regions.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the cell therapy manufacturing market. Based on parameters, such as number of ongoing/planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such products, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2019-2030.

In addition, to account for the uncertainties associated with the manufacturing of cell-based therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Market Insights

Till date, more than 20 cell-based therapies have been approved (recent examples include Zynteglo (2019), Alofisel (2018), YESCARTA (2017) and Kymriah (2017)), while over 500 product candidates are under development. In fact, there are over 1,000 active clinical studies of cell therapies, worldwide. Over the last few years, such therapies have garnered significant attention within the biopharmaceutical industry. Several companies and venture capital funds/investors have already invested a lot of capital towards the development and commercialization of this emerging class of therapeutics.

Despite the optimism, the growth in this domain is still hindered by various development and manufacturing related challenges, primarily due to the limited availability of expertise and infrastructure to produce cell-based therapies, such as CAR-T cell therapies.

The growing number of product development initiatives in this domain, coupled to the fact that there are multiple marketed products, have led to a substantial rise in the overall cell therapy manufacturing demand. As a result, developers have turned to contract manufacturing organizations (CMOs) to fulfil their cell therapy development and production requirements.

A wide array of industry players, including well-established companies, mid-sized firms and start-ups, as well as academic institutes, are contributing towards fulfilling the aforementioned demand, offering GMP grade manufacturing services for cell therapies. In addition to cell therapy manufacturing companies, there are several other players that claim to have developed novel technology solutions, aimed at improving the existing cell therapy manufacturing process.

Many CMOs are also actively expanding their cell therapy manufacturing capacity either through collaborations or acquisitions, in order to offer a wide range of services to their respective clients. As a result of the ongoing efforts aimed at mitigating the existing challenges in this domain, the cell therapy manufacturing market is expected to witness significant growth in mid-long term.

Amongst other elements, the report includes:

A detailed review of the overall landscape of companies that are engaged in the manufacturing of cell-based therapies, including information on the type of cells manufactured (including immune cells (including T cells, dendritic cells, NK cells), stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cells (autologous and allogeneic), scale of manufacturing, type of cell cultures (adherent and suspension), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities/services offered (including R&D, cell culture development, quality testing, packaging, labelling, cell banking, cryopreservation, fill/finish services, and regulatory affairs management), location of headquarters and location of their respective manufacturing facilities.
An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective cell therapy manufacturing capabilities, over the period 2015-2019 (till October), taking into consideration parameters, such as year of expansion, type of cells, scale of operation, purpose of expansion (facility expansion and new facility), location of manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).
An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established in the period 2014-2019 (till November), based on various relevant parameters, such as the year of agreement, type of partnership, type of cells, and scale of operation (preclinical, clinical and commercial).
Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of cells produced and area dedicated to manufacturing), which were further analyzed based on type of cells.
An estimate of the overall, installed capacity for manufacturing cell-based therapies based on information reported by industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), size of the organization (small, mid-sized and large firms) and key geographical regions (North America, EU and Asia Pacific).
An in-depth analysis of cell therapy manufacturers using three versatile representations, namely [A] a three-dimensional grid analysis, presenting the distribution of companies on the basis of type of cells manufactured, scale of operation and purpose of production, [B] a logo landscape based on the type of cells manufactured, geographical location of manufacturer (North America, Europe and Asia Pacific) and type and size of organization (non-industry players, and small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical locations of cell therapy manufacturing facilities of both industry and non-industry stakeholders.
A detailed analysis of the various factors that are likely to influence the pricing of cell-based therapies, featuring different models/approaches that may be adopted by manufacturers while deciding the prices of their proprietary offerings.
An elaborate discussion on the role of automation technologies in improving current manufacturing methods, along with a comparative (qualitative) analysis of cost differences between manual and automated processes.
A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
A discussion on cell therapy manufacturing regulations across various geographies, including the North America (focusing on the US), Europe and Asia (focusing on Japan), featuring an analysis of the diverse certifications/accreditations awarded to manufacturing facilities by important regulatory bodies across the globe.
Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies; each profile includes an overview of the company/organization, information on its manufacturing facilities, service portfolio details, recent partnerships and an informed future outlook.
A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under a comprehensive SWOT framework, which includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics.
Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly and indirectly involved in the development and/or manufacturing of cell-based therapies.

Key Topics Covered

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Introduction to Cell Therapies
3.2.1. Comparison of Cell Therapies and Other Biotechnology Products
3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
3.2.3. Current Market Landscape of ATMPs
3.3. Overview of Cell Therapy Manufacturing
3.4. Cell Therapy Manufacturing Models
3.4.1. Centralized Manufacturing
3.4.2. Decentralized Manufacturing
3.5. Scalability of Cell Therapy Manufacturing
3.5.1. Scale-up
3.5.2. Scale-out
3.6. Types of Cell Therapy Manufacturers
3.7. Key Manufacturing-related Challenges
3.8. Factors Influencing Cell Therapy Manufacturing
3.9. Automating Cell Therapy Manufacturing
3.10. Cell Therapy Manufacturing Supply Chain
3.11. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Cell Therapy Manufacturers (Industry Players): Overall Market Landscape
4.2.1. Analysis by Location of Headquarters
4.2.2. Analysis by Location of Manufacturing Facility
4.2.3. Analysis by Type of Cells Manufactured
4.2.4. Analysis by Source of Cells
4.2.5. Analysis by Scale of Operation
4.2.6. Analysis by Type of Cell Culture
4.2.7. Analysis by Purpose of Production
4.2.8. Analysis by Manufacturing Capabilities/Services
4.3. Cell Therapy Manufacturers (Non-Industry Players): Overall Market Landscape
4.3.1. Analysis by Location of Headquarters
4.3.2. Analysis by Location of Manufacturing Facility
4.3.3. Analysis by Type of Cells Manufactured
4.3.4. Analysis by Source of Cells
4.3.5. Analysis by Scale of Operation
4.3.6. Analysis by Type of Cell Culture
4.3.7. Analysis by Purpose of Production
4.3.8. Analysis by Manufacturing Capabilities/Services
4.4. Cell Therapy Manufacturing: Role of Logistics Service Providers

5. REGULATORY LANDSCAPE
5.1. Chapter Overview
5.2. Current Scenario
5.2.1. Regulatory Guidelines in the US
5.2.2. Regulatory Guidelines in Europe
5.2.3. Regulatory Guidelines in Japan
5.2.4. Conditional Approvals
5.3. Regulatory Accreditations for Cell Therapy Manufacturing
5.3.1. Facilities Approved by Regulators to Manufacture Cell Therapies
5.4. Summary of Guidelines for Clinical-Stage Manufacturing of Cell Therapies
5.5. Existing Challenges to Clinical-Stage Manufacturing
5.5.1. Variability in Regulatory Guidelines across Different Geographies
5.6. Conclusion

6. ROADMAPS FOR OVERCOMING EXISTING CHALLENGES
6.1. Chapter Overview
6.2. Roadmap for the US
6.2.1. Cell Processing
6.2.2. Cell Preservation, Distribution and Handling
6.2.3. Process Automation and Data Analytics
6.2.4. Process Monitoring and Quality Control
6.2.5. Standardization and Regulatory Support
6.2.6. Workforce Development
6.2.7. Supply Chain and Logistics
6.3. Roadmaps for Other Geographies
6.3.1. Europe
6.3.2. Asia Pacific

7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
7.1. Chapter Overview
7.2. Automation of Cell Therapy Manufacturing Processes
7.2.1. Closed Systems
7.2.2. Single-use Systems
7.2.3. Modular Systems
7.3. Case Studies
7.3.1. Roadmap to Developing an Automated Cell Manufacturing/Processing Device
7.3.2. Automating Cell Therapy Manufacturing
7.4. GMP-in-a-Box
7.5. List of Automation Service Providers
7.6. Comparative Analysis of Manual and Automated Processes
7.7. Concluding Remarks

8. PROFILES: INDUSTRY PLAYERS
8.1. Chapter Overview
8.2. Service Providers in the US
8.2.1 Cognate BioServices
8.2.1.1. Company Overview
8.2.1.2. Service Portfolio
8.2.1.3. Manufacturing Capabilities
8.2.1.4. Partnerships
8.2.1.5. Future Outlook
8.2.2. FUJIFILM Cellular Dynamics
8.2.3. KBI Biopharma
8.2.4. Hitachi Chemical Advanced Therapeutics Solutions
8.2.5. Waisman Biomanufacturing
8.3. Service Providers in Europe
8.3.1. BioNTech Innovative Manufacturing Services
8.3.2. Cell and Gene Therapy Catapult
8.3.3. Lonza
8.3.4. MaSTherCell
8.3.5. Roslin Cell Therapies
8.4. Service Providers in Asia Pacific
8.4.1. Cell Therapies
8.4.2. Japan Tissue Engineering (J-TEC)
8.4.3. MEDINET
8.4.4. Nikon CeLL innovation
8.4.5. WuXi Advanced Therapies

9. PROFILES: NON-INDUSTRY PLAYERS
9.1. Chapter Overview
9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
9.2.1. Overview
9.2.2. Operating Segments
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities
9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
9.5. Guy's and St. Thomas' GMP Facility, Guy's Hospital
9.6. Laboratory for Cell and Gene Medicine, Stanford University
9.7. Molecular and Cellular Therapeutics, University of Minnesota
9.8. Newcastle Cellular Therapies Facility, Newcastle University
9.9. Rayne Cell Therapy Suite, King's College London
9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
9.11. Sydney Cell and Gene Therapy

10. ROLE OF NON-PROFIT ORGANIZATIONS
10.1. Chapter Overview
10.2. Cell Therapy Manufacturing Service Providers: Non-Profit Organizations
10.2.1. CellCAN
10.2.2. Cell Therapy Manufacturing Cooperative Research Center (CTM CRC)
10.2.3. National Cell Manufacturing Consortium (NCMC)
10.2.4. California Institute of Regenerative Medicine (CIRM)
10.3. Cell Therapy Manufacturing: Affiliated International Societies

11. PARTNERSHIPS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Cell Therapy Manufacturing: List of Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership Model
11.3.3. Analysis by Year and Type of Partnership Model
11.4. Analysis by Type of Cells
11.5. Analysis by Scale of Operation
11.6. Geographical Analysis
11.6.1. Continent-wise Distribution
11.6.2. Country-wise Distribution
11.7. Most Active Players: Analysis by Number of Partnerships
11.8. Cell Therapy Manufacturing: List of Acquisitions
11.8.1. Analysis by Year and Type of Cells
11.8.2. Geographical Analysis
11.8.3. Ownership Change Matrix

12. FACILITY EXPANSIONS
12.1. Chapter Overview
12.2. Cell Therapy Manufacturing: List of Expansions
12.2.1. Cumulative Year-wise Distribution
12.2.2. Analysis by Type of Cells
12.2.3. Analysis by Scale of Operation
12.2.3. Analysis by Purpose of Expansion
12.2.4. Analysis by Location of Manufacturing Facility
12.2.5. Analysis by Region and Purpose of Expansion

13. CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology (Industry Players)
13.2.1 Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
13.2.1.1. Analysis by Size of Manufacturer
13.2.1.2. Analysis by Scale of Operation
13.2.1.3. Analysis by Location of Manufacturing Facility
13.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
13.3. Key Assumptions and Methodology (Non-Industry Players)
13.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
13.3.1.1. Analysis by Scale of Operation
13.3.1.2. Analysis by Location of Manufacturing Facility
13.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
13.4 Concluding Remarks

14. DEMAND ANALYSIS
14.1 Chapter Overview
14.2 Key Assumptions and Methodology
14.3 Cell Therapy Manufacturing: Overall Annual Demand
14.3.1. Analysis by Type of Cells
14.3.2. Analysis by Scale of Operations
14.3.3. Analysis by Geography

15. COST PRICE ANALYSIS
15.1. Chapter Overview
15.2. Factors Contributing to the High Price of Cell Therapies
15.3. Pricing Models for Cell Therapies
15.3.1. Based on Associated Costs for T-cell Therapies
15.3.2. Based on Associated Costs for Stem Cell Therapies
15.3.3. Based on Availability of Competing Products
15.3.4. Based on Target Patient Segment
15.3.5. Based on Opinions of Industry Experts
15.4. Cell Therapy Cost Optimization
15.4.1. Role of Cost of Goods Sold
15.4.2. Role of Automation
15.4.3. Role of Cell Therapy Contract Manufacturing Organizations
15.5. Reimbursement-related Considerations for Cell Therapies
15.5.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
16.1. Chapter Overview
16.2. Make versus Buy Decision Making: Analytical Output

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope of the Forecast
17.3. Forecast Methodology
17.4. Input Tables and Key Assumptions
17.5. Overall Cell Therapy Manufacturing Market, 2019-2030
17.5.1. Cell Therapy Manufacturing Market, 2019-2030: Distribution by Type of Cell Therapy
17.5.2. Cell Therapy Manufacturing Market, 2019-2030: Distribution by Source of Cells
17.5.3. Cell Therapy Manufacturing Market, 2019-2030: Distribution by Scale of Operation
17.5.4. Cell Therapy Manufacturing Market, 2019-2030: Distribution by Purpose of Production
17.5.5. Cell Therapy Manufacturing Market, 2019-2030: Geographical Distribution
17.6. Market Opportunity in Commercial Scale Manufacturing of Cell-based Therapies
17.7. Market Opportunity in Clinical Scale Manufacturing of Cell-based Therapies

18. KEY INSIGHTS
18.1. Chapter Overview
18.2. Cell Therapy Manufacturers: Grid Analysis
18.3. Cell Therapy Manufacturers: Logo Landscape by Type of Cell Therapy
18.3.1. Logo Landscape: Immune Cell Manufacturers
18.3.2. Logo Landscape: Stem Cell Manufacturers
18.4. Cell Therapy Manufacturers: World Map Representation of Location of Manufacturing Facility
18.4.1. Industry Players
18.4.2. Non-Industry Players

19. SWOT ANALYSIS
19.1. Chapter Overview
19.2. Strengths
19.3. Weaknesses
19.4. Opportunities
19.5. Threats
19.6. Comparison of SWOT Factors
19.6.1. Concluding Remarks

20. CONCLUSION
20.1. Chapter Overview
20.2. Key Takeaways

21. SURVEY ANALYSIS
21.1. Chapter Overview
21.2. Seniority Level of Respondents
21.3. Type of Cell Therapy
21.4. Scale of Operation
21.5. Source of Cells
21.6. Type of Cell Culture System
21.7. Availability of Fill/Finish Services

22. INTERVIEW TRANSCRIPTS
22.1. Chapter Overview
22.2. Lion TCR
22.2.1. Company Overview
22.2.2. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
22.3. Cell Therapies
22.4. CiMaas
22.5. Gracell Biotechnologies
22.6. Glycostem Therapeutics
22.7. Kadimastem
22.8. Bio Elpida
22.9. Center for Commercialization of Cancer Immunotherapy/C3i
22.10. Waisman Biomanufacturing
22.11. RoslinCT
22.12. Yposkesi
22.13. University of Minnesota

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

3P Biopharmaceuticals
A2 Healthcare
Accellta
Acerta Pharma
Adaptimmune
Adva Biotechnology
Advanced Cell Therapy Laboratory, Yale School of Medicine
Advanced Regenerative Manufacturing Institute
Advent Bioservices
Agios Pharmaceuticals
Ajinomoto
Akron Biotech
Alberta Cell Therapy Manufacturing, University of Alberta
Allele Biotechnology & Pharmaceuticals
Alliance for Regenerative Medicine
AlloSource
Altor BioScience
American Productivity & Quality Center
American Society of Gene and Cell Therapy
American Society of Mechanical Engineers
Amgen
Amsterdam Biotherapeutics Unit
Andalusian Initiative for Advanced Therapies
Angiocrine Bioscience
Anterogen
Aokai (Suzhou) Biomedical
apceth Biopharma
Argos Therapeutics
ARIAD Pharmaceuticals
Asahi Glass Company
Asterias Biotherapeutics
AstraZeneca
Asymptote
Atara Biotherapeutics
Athersys
Atlantic Bio GMP
ATVIO Biotechnology
Australasian Gene and Cell Therapy Society
Austrian Network for Gene Therapy
Autolus
Azellon Cell Therapeutics
Bavarian Nordic
Bayer
Be The Match BioTherapies
Bellicum Pharmaceuticals
Berkeley Lights
Bio Elpida
BioCision
Bioinova
BioLife Solutions
Biological and Cellular GMP Manufacturing Facility, City of Hope
biologistex CCM
BioNTech Innovative Manufacturing Services
Biosafe Group
bluebird bio
Boehringer Ingelheim
Bone Therapeutics
Brammer Bio
Bristol-Myers Squibb
British Society for Gene and Cell Therapy
Caladrius Biosciences
California Institute of Regenerative Medicine
Cancer Research UK
Capricor Therapeutics
CardioCell
Celgene
Cell and Gene Therapy Catapult
Cell Manipulation Core, Dana-Farber / Harvard Cancer Center
Cell Medica
Cell Tech Pharmed
Cell Therapies
Cell Therapy and Regenerative Medicine, University of Utah
Cell Therapy Facility, UMC Utrecht
Cell Therapy Manufacturing Cooperative Research Center
Cell Therapy Suite, University of Birmingham
Cellab
CellCAN
Cellectis
CELLforCURE
Cellin Technologies
Cells Cure Foundation
Cells for Sight Stem Cell Therapy Research Unit, University College London
Cellular Biomedicine Group
Cellular Therapeutics
Cellular Therapy Core, University of Texas
Cellular Therapy Integrated Services, Case Western Reserve University
Celyad
Censo Biotechnologies
Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
Center for Cell and Gene Therapy, Baylor College of Medicine
Center for Gene and Cell Processing, Takara Bio
Center for International Blood and Marrow Transplant Research
Centre for Biological Engineering, Loughborough University
Centre for Cell and Vector Production
Centre for Cell Manufacturing Ireland, NUI Galway
Centre for Commercialization of Regenerative Medicine
Centre for Stem Cell Research
Centre for Commercialization of Cancer Immunotherapy (C3i)
Centre multidisciplinaire de dveloppement du gnie tissulaire
Centre of Genomics and Policy, McGill University
Cesca Therapeutics
Chemometec
Chiesi Farmaceutici
Children's Medical Research Institute
Children's GMP, St. Jude Children's Research Hospital
China Life Health Industry Group
China Regenerative Medicine International
CiMaas
City of Hope Alpha Clinic for Cell Therapy
Clinical Biomanufacturing Facility, University of Oxford
Clinical Cell and Vaccine Production Facility
Clinical Research Facility, South London and Maudsley
Closed Cell Systems
Cognate BioServices
Commonwealth Scientific and Industrial Research Organization
Cook MyoSite
CRISPR Therapeutics
Cryoport
Cryosite
CureCell
Cynata Therapeutics
Cytonome
Cytori Therapeutics
CyTuVax
DanDrit Biotech
DCPrime
Dendreon
DiscGenics
Eli Lilly
EMERCell
Emory Personalized Immunotherapy Core
European Bank for induced pluripotent Stem Cells
European Society of Gene and Cell Therapy
Federal Economic Development Agency for Southern Ontario
Ferrologix
Fibrocell
Finnish Gene Therapy Society
Fisher BioServices
FloDesign Sonics
Fortuna Fix
Fosun Pharma
Foundation for the Accreditation of Cellular Therapy
Foundation of Croatian Association for Regenerative Medicine and Stem Cell Therapy
Fraunhofer Institute for Cell Therapy and Immunology IZI
French Society of Cellular and Gene Therapy
Froceth
FUJIFILM Cellular Dynamics
Gamida Cell
Gates Biomanufacturing Facility
GC Cell
GE Healthcare
GenCure
Gene and Cell Therapy Lab, Institute of Translational Health Sciences
Genentech
Georgia Institute of Technology
Georgia Research Alliance
German Gene Therapy Society
Gilead Sciences
GlaxoSmithKline
Glycostem Therapeutics
GPB Scientific
Gradalis
Great Ormond Street Hospital Cellular Therapy Laboratories, University College London
Guy's and St Thomas' Facility
Haematological Sciences, Institute of Cellular Medicine
Harvard University Stem Cell Institute
Health Sciences Authority
Hielscher Ultrasonics
Histocell
Hitachi Chemical Advanced Therapeutics Solutions
Holostem Terapie Avanzate
Hospital of University of Pennsylvania
Houston Methodist Hospital Foundation
Houston Methodist Institute of Technology, Innovation and Education
Houston Methodist Research Institute
Human Islet and Cellular Transplant Facility
Human Stem Cells Institute
Immatics Biotechnologies
ImmunoCellular Therapeutics
Immunocore
Immunovative Therapies
IncoCell Tianjin
Innovate UK
Innovative Cellular Therapeutics
IntelliCell BioSciences
Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
International Cellular Medicine Society
International Society for Cancer Gene Therapy
International Society for Cellular Therapy
International Society for Stem Cell Research
International Stem Cell Corporation
Invetech
Iovance Biotherapeutics
IQVIA Stem Cell Center
Irish Society for Gene and Cell Therapy
Irish Stem Cell Foundation
Israeli Society for Gene and Cell Therapy
Isto Biologics
Japan Society for Gene Therapy
Japan Tissue Engineering
Jazz Pharmaceuticals
JCR Pharmaceuticals
John Goldmann Centre for Cellular Therapy, Imperial College London
Juno Therapeutics
JW CreaGene
Kawasaki Heavy Industries
KBI Biopharma
Kiadis Pharma
Kids Research Institute
Kite Pharma
KMC Systems
Kolon TissueGene
Korean Society of Gene and Cell Therapy
Laboratory for Cell and Gene Medicine, University of Stanford
Lexicon Pharmaceuticals
Lion TCR
Lonza
Maisonneuve-Rosemont Hospital
Marken
MaSTherCell
Mayo Clinic Center for Regenerative Medicine
MedCision
Medigene
MEDINET
MEDIPOST
Medistem Panama (Stem Cell Institute)
MedPost
MedStar Georgetown University Hospital
Merck
Mesoblast
Michael Smith Laboratories, University of British Columbia
Millennium Pharmaceuticals
Millipore Sigma
Miltenyi Biotec
MNX Global Logistics
Moffitt Cancer Center
Molecular and Cellular Therapeutics, University of Minnesota
MolMed
Mustang Bio
Nantes University Hospital
National Cell Manufacturing Consortium
National Centre for Biomedical Engineering Sciences
National Eye Institute
National Gene Vector Laboratory
National Institute of Health Research
National Institute of Standards and Technologies
National Stem Cell Foundation
National Stem Cell Foundation of Australia
Neon Therapeutics
Netherlands Cancer Institute
Networks of Centres of Excellence
Neuralstem
NewLink Genetics
NHSBT Blood and Transplant, Birmingham
Nikon
Nikon CeLL innovation
Nohla Therapeutics
Northwest Biotherapeutics
Norwegian Radium Hospital
Novadip
Novartis
NuVasive
Octane Medical Group
Oncobiomed
Ontario Institute of Regenerative Medicine
Onyx Pharmaceuticals
Opexa Therapeutics
Orchard Therapeutics
Orgenesis
Orthofix
Ospedale Pediatrico Bambino Ges
Ottawa Hospital Research Institute, University of Ottawa
Oxford BioMedica
Oxford MEStar
Pall
PAREXEL
PCI Services
PCT Cell Therapy Services
The Peter Couche Foundation
Peter MacCallum Cancer Centre
Pfizer
PharmaBio
PharmaCell
Pharmicell
Pluristem Therapeutics
Praxis Pharmaceutical
Production Assistance for Cellular Therapies
Promethera Biosciences
Provia Laboratories
Puma Biotechnology
Q-GEN Cell Therapeutics, QIMR Berghofer Medical Research Institute
Rayne Cell Therapy Suite, King's College London
Regenerative Medicine Foundation
Regenerative Medicine Institute
Regenesys
Regeneus
Reliance Life Sciences
ReNeuron
RepliCel
Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
Riyadh Pharma
Robertson Clinical and Translational Cell Therapy, Duke University
Roche Diagnostics
RoosterBio
Roslin Cells
Roswell Park Cancer Institute
Royal Free Hospital, Centre for Cell and Gene Tissue Therapeutics
Royal Prince Alfred Hospital
Saint-Gobain
SanBio
Sartorius Stedim Biotech
SAVSU Technologies
Scinogy
Scottish Centre for Regenerative Medicine
Scottish National Blood Transfusion Service Cellular Therapy Facility
Servier
Shanghai Sunway Biotech
Shenzhen Sibiono GeneTech
SHIBUYA
Sistemic
Smilow Center for Translational Research
Smith & Nephew
SOTIO
Spanish Society for Gene and Cell Therapy
Spark Therapeutics
Stage Cell Therapeutics
Stanford Children's Health, Stanford Health Care
Stanford Medicine
Stemedica Cell Technologies
Sumitomo Dainippon Pharma
Swedish Society for Gene and Cell Therapy
Sydney Cell and Gene Therapy
Syngen Biotech
Takeda Pharmaceutical
TAP Biosystems
TargetAMD
TC BioPharm
T-Cell Factory
Terumo
Terumo BCT
TESARO
Texas Children's Hospital
Texas Medical Center
The Children's Hospital at Westmead
The Elisa Linton Center for Rare Disease Therapies
The Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
The Netherlands Society of Gene and Cell Therapy
The New York Stem Cell Foundation
The Ottawa Hospital Research Institute
The Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
The University of Texas Health Science Center
Therapeutic Cell Production Core, Seattle Children's Hospital
Thermo Fisher Scientific
ThermoGenesis
TiGenix
Tokyo Electron
TrakCel
Trinity Partners
Turkish Society for Gene and Cell Therapy
TVAX Biomedical
TxCell
Tyne Hospitals NHS Foundation Trust
UC Davis GMP Laboratory
UCLA Human Gene and Cell Therapy
UCLA-UCI Alpha Stem Cell Clinic
UK Stem Cell Foundation
University Hospital Basel
University Medical Center Groningen
University of California
University of Leeds
University of Manchester
University of Newcastle
University of North Carolina Lineberger Comprehensive Cancer Center
University of Tennessee
University of Wisconsin-Madison
Upstate Stem Cell cGMP Facility, University of Rochester
Vaccinogen
Valeant Pharmaceuticals
Vecura, Karolinska University Hospital
Vericel
Vineti
Vitruvian Networks
VivaBioCell
Waisman Biomanufacturing
Westmead Hospital
Westmead Millennium Institute
World Courier
WuXi Advanced Therapies
WuXi AppTec
Wyeth
Xellbiogene
Yposkesi
Zelluna Immunotherapy

For more information about this report visit https://www.researchandmarkets.com/r/r2szhz

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets